Oppenheimer Maintains Outperform on Astria Therapeutics, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh has maintained an Outperform rating on Astria Therapeutics (NASDAQ:ATXS) but has reduced the price target from $30 to $25.
November 15, 2023 | 6:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Astria Therapeutics but lowers the price target from $30 to $25.
The reduction in price target by Oppenheimer, despite maintaining an Outperform rating, could lead to a negative perception among investors, potentially causing short-term downward pressure on ATXS's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100